Glucosamine chondroitin composition and preparation method thereof

Abstract

The invention discloses a glucosamine chondroitin composition and a preparation method thereof, and belongs to the field of health care products. The composition is prepared from turmeric extract, rhizoma drynariae extract, eucommia ulmoides extract, prepared rehmannia root extract, vitamin K, bovine bone collagen peptide, chondroitin sulfate, glucosamine hydrochloride and milk calcium. The rhizoma curcumae longae extract, the rhizoma drynariae extract, the cortex eucommiae extract, the radix rehmanniae praeparata extract, the vitamin K, the bovine bone collagen peptide, the chondroitin sulfate, the glucosamine hydrochloride and the milk calcium are compounded for use, so that an excellent effect of enhancing the bone mineral density is achieved.

Description

Technical Field

[0001] The present invention relates to the field of health products, and particularly relates to a glucosamine chondroitin composition and a preparation method thereof. Background Art

[0002] Bone mineral density is an important indicator to measure the health status of bones. A decrease in bone mineral density may have a profound impact on individual health. For example, a decrease in bone mineral density not only leads to osteoporosis and increases the risk of fractures, but may also trigger various complications, seriously affecting the quality of life of patients. Fracture is one of the most serious consequences of osteoporosis, especially hip fracture, which has a very high disability and fatality rate. In addition, a decrease in bone mineral density may also cause appearance changes such as shortening of height and kyphosis, bringing psychological burden to patients.

[0003] Calcium is a key nutrient for maintaining bone mineral density. The calcium content in human bones accounts for about 99% of the total body calcium. With the influence of factors such as aging, hormonal level changes, or bad lifestyle, the loss of calcium accelerates and the bone mineral density gradually decreases. Therefore, supplementing calcium has become one of the important means for preventing and treating the decrease in bone mineral density.

[0004] Glucosamine chondroitin calcium tablets are a common health product for preventing and treating osteoarticular diseases. However, the current glucosamine chondroitin calcium tablets on the market often have some problems, such as a relatively short duration of drug effect and the need for frequent administration. Moreover, long-term high-dose administration of glucosamine chondroitin calcium tablets will cause side effects such as gastrointestinal discomfort, headache, and dizziness. Therefore, how to improve the calcium supplementation efficacy of glucosamine chondroitin calcium tablets by adding other ingredients has become a current research hotspot. Summary of the Invention

[0005] The purpose of the present invention is to provide a glucosamine chondroitin composition and a preparation method thereof. The glucosamine chondroitin composition is prepared from turmeric extract, drynaria rhizome extract, eucommia bark extract, rehmannia root extract, vitamin K, bovine bone collagen peptide, chondroitin sulfate, glucosamine hydrochloride, and milk calcium as raw materials, and has excellent effects of enhancing calcium absorption and enhancing bone mineral density.

[0006] In order to achieve the above purpose, the present invention adopts the following technical solutions: In the first aspect, the present invention provides a glucosamine chondroitin composition, and the glucosamine chondroitin composition comprises the following raw materials in parts by mass: Turmeric extract: 2 - 4 parts; Drynaria rhizome extract: 5 - 8 parts; Eucommia bark extract: 4 - 7 parts; Rehmannia root extract: 3 - 5 parts; Vitamin K: 2 - 6 parts; Bovine bone collagen peptide: 5 - 10 parts; Chondroitin sulfate: 2 - 4 parts; Glucosamine Hydrochloride: 3 - 6 parts; Milk Calcium: 20 - 30 parts; The vitamin K is composed of vitamin K1 and vitamin K2, and the mass ratio of vitamin K1 to vitamin K2 is 1:0.5 - 1.5.

[0007] Preferably, the glucosamine chondroitin composition comprises the following raw materials in parts by mass: Turmeric Extract: 3 parts; Drynaria Rhizome Extract: 6 parts; Eucommia ulmoides Oliv. Extract: 6 parts; Prepared Rehmannia Root Extract: 4 parts; Vitamin K: 4 parts; Bovine Bone Collagen Peptide: 7 parts; Chondroitin Sulfate: 3 parts; Glucosamine Hydrochloride: 5 parts; Milk Calcium: 25 parts; The vitamin K is composed of vitamin K1 and vitamin K2, and the mass ratio of vitamin K1 to vitamin K2 is 1:1.

[0008] In a second aspect, the present invention provides a calcium tablet having the effects of preventing calcium loss, promoting calcium absorption, and protecting joints. The calcium tablet comprises the following components in parts by mass: The glucosamine chondroitin composition described in the first aspect: 50 - 60 parts; Magnesium Oxide: 5 - 10 parts; Magnesium Stearate: 0.5 - 2 parts; Xylitol: 5 - 15 parts; Sorbitol: 2 - 5 parts; Vitamin D3: 0.1 - 0.3 parts; 3wt% Povidone K30 Solution: 5 - 6 parts; The 3wt% Povidone K30 solution is prepared by dissolving povidone K30 in absolute ethanol.

[0009] In a third aspect, the present invention provides a preparation method for the calcium tablet described in the second aspect. The preparation method comprises the following steps: S1. Pass magnesium oxide, xylitol, sorbitol, and vitamin D3 through an 80 - mesh sieve respectively and then mix them to obtain a mixture. Add the povidone K30 solution to the mixture to make wet granules, and granulate with a 16 - mesh sieve shaker; S2. Dry the granules obtained in S1 at 38°C for 0.5 - 1 h, and then screen them with a 20 - mesh sieve; S3. Mix the granules obtained in S2 and magnesium stearate evenly by the equal - increment method, and press tablets with a tablet press to obtain the finished calcium tablets, and then bottle them.

[0010] Compared with the prior art, the beneficial effects of the present invention are as follows: The present invention provides a glucosamine chondroitin composition, which is compounded from turmeric extract, drynaria rhizome extract, eucommia bark extract, rehmannia root extract, vitamin K, bovine bone collagen peptide, chondroitin sulfate, glucosamine hydrochloride, and milk calcium. Among them, turmeric extract and rehmannia root extract have anti-inflammatory and antioxidant effects, and can reduce bone loss by inhibiting inflammatory reactions and regulating osteoclast activity; drynaria rhizome extract and eucommia bark extract have the effects of tonifying the kidney and strengthening bones, promoting blood circulation and removing blood stasis, and can promote the generation and repair of bone cells; bovine bone collagen provides a rich collagen matrix for bones and can promote calcium deposition and bone tissue repair; vitamin K can promote osteocalcin synthesis and fix calcium ions in the bone matrix; glucosamine hydrochloride and chondroitin sulfate can repair articular cartilage and reduce joint wear; milk calcium can directly supplement calcium. The above raw materials synergistically enhance the effects through multiple pathways. On the one hand, they directly supplement calcium and promote absorption and deposition. On the other hand, they regulate bone metabolism, repair bone tissue, and enhance bone toughness, comprehensively improving bone density and bone health. Detailed implementation manners

[0011] To better understand the present invention, the following describes the present invention in further detail with reference to specific application examples. The terms used in the application examples are for describing specific implementation manners and do not constitute a limitation to the protection scope of the present invention.

[0012] For the experimental methods without specific conditions noted in the following examples, they are usually carried out under conventional conditions or according to the conditions recommended by the manufacturer. Unless otherwise specified, calculations are based on mass percentages and mass parts.

[0013] The sources of some raw materials are as follows: Turmeric extract: Purchased from Shanxi Lanyuan Biotechnology Co., Ltd., product number: lysw-0825-366; Drynaria rhizome extract: Purchased from Shanxi Hongchuang Biotechnology Co., Ltd., product number: SXHC-0706-111; Eucommia bark extract: Purchased from Shaanxi Xintianyu Biotechnology Co., Ltd., product number: XTYDZ01; Rehmannia root extract: Purchased from Shaanxi Xinyanghe Biotechnology Co., Ltd., product number: XYH-SDH-001; Vitamin K1: Purchased from Anhui Weimao Biotechnology Co., Ltd.; Vitamin K2: Purchased from Jiangsu Baiyao Biotechnology Co., Ltd.; Bovine bone collagen peptide: Purchased from Shanxi Shangnuoda Biotechnology Co., Ltd., product number SND-NGJYDBT; Chondroitin sulfate: Purchased from Lanli Biotechnology (Xi'an) Co., Ltd., product number LL-202212101; Glucosamine Hydrochloride: Purchased from Guangzhou Huiding Food Co., Ltd.; Milk Calcium: Purchased from Guangzhou Quanfeng Food Technology Co., Ltd.; Other raw materials were all purchased commercially.

[0014] The raw materials of the glucosamine chondroitin composition and their parts by mass are shown in Table 1.

[0015] Table 1 Raw materials of the glucosamine chondroitin composition and their parts by mass

[0016] Efficacy determination Test 1: Bone density test Test samples: Composition 1, Compositions ① - ⑥. Each composition was prepared into a 100 mg / mL mixed solution with deionized water, and the feeding amounts are shown in Table 2.

[0017] Test animals: OVX (bilateral ovariectomy) model SD rats weighing 250 ± 5 g (purchased from Jintai Meidi Biotechnology Co., Ltd.). The OVX model SD rats were analyzed and grouped into 7 test groups and 1 control group, with 9 rats in each group.

[0018] The feed used for the test animals was AIN - 93M type standard feed, purchased from Xiaoshu Youtai (Beijing) Biotechnology Co., Ltd.

[0019] Test period: 12 weeks.

[0020] Test method: During the test period, the test groups were intragastrically administered the test samples daily, and the control group was intragastrically administered an equal amount of deionized water. After the end of the test period, the rats were anesthetized with 3.5 w / v% chloral hydrate (10 μL / g) within 1 h, and the bone density of the right femur of the rats was measured using a dual - energy X - ray bone densitometer. The results were expressed as mean ± standard deviation.

[0021] Table 2 Bone density efficacy determination Experimental group Test sample Feeding amount <![CDATA[Mean bone mineral density of mice (g / cm 3 )]]> Control group Deionized water 0.008 mL / g·d 0.196±0.04 Experimental group 1 Composition 1 0.008 mL / g·d <![CDATA[0.357±0.05 * > Experimental group ① Composition ① 0.008 mL / g·d <![CDATA[0.274±0.03 * > Experimental group ② Composition ② 0.008 mL / g·d <![CDATA[0.251±0.06 * > Experimental group ③ Composition ③ 0.008 mL / g·d <![CDATA[0.223±0.04 * > Experimental group ④ Composition ④ 0.008 mL / g·d <![CDATA[0.316±0.06 * > Experimental group ⑤ Composition ⑤ 0.008 mL / g·d <![CDATA[0.295±0.03 * > Experimental group ⑥ Composition ⑥ 0.008 mL / g·d <![CDATA[0.302±0.07 * > Note: "*" indicates that compared with the control group, p < 0.05, showing a significant difference.

[0022] From the comparison between Composition 1 and Compositions ① - ⑥ in Table 1, it can be seen that the glucosamine chondroitin composition described in the present invention has the efficacy of improving bone density.

[0023] From the comparison of the results of Composition 1 and Compositions ① - ③, it can be seen that the curcumin extract, rehmannia root extract and vitamin K in the glucosamine chondroitin composition described in the present invention can effectively synergize with other raw materials to improve the efficacy of bone density.

[0024] By comparing the results of Composition 1 and Compositions ④-⑤, it can be seen that the mass ratio of vitamin K1 to K2 in vitamin K in the glucosamine chondroitin composition of the present invention has a certain impact on the improvement of bone density.

[0025] By comparing the results of Composition 1 and Composition ⑥, it can be seen that the dosage ratio between the raw materials in the present invention has a certain impact on the improvement of bone density. Within the range of the mass ratio described in the present invention, glucosamine chondroitin has a better effect on improving bone density.

[0026] Experiment 2: Acute toxicity test Test substances: Compositions 1-3; Using deionized water, Compositions 1-3 were prepared into a 1 g / mL mixed solution.

[0027] Acute toxicity experiment: 60 SD rats with a body weight of 250 ± 5 g were selected, with 30 males and 30 females; Environment: temperature 23 ± 1°C, humidity 54 ± 2%.

[0028] The mixed solutions of Compositions 1-3 samples were orally administered to rats by gavage once, and the doses are shown in Table 3. The rats were fasted for 16 hours before gavage, and were continuously observed for two weeks after gavage. The poisoning manifestations and death conditions were recorded, as shown in Table 3. During the gavage period, the rats were normally fed with AIN-93M standard feed.

[0029] Table 3 Acute toxicity test of mice Group Gender Route Dose Number of deaths (only) Composition 1 Male Oral 0.008 mL / g·d 0 Composition 1 Female Oral 0.008 mL / g·d 0 Composition 2 Male Oral 0.008 mL / g·d 0 Composition 2 Female Oral 0.008 mL / g·d 0 Composition 3 Male Oral 0.008 mL / g·d 0 Composition 3 Female Oral 0.008 mL / g·d 0 From the results of the acute toxicity test, it can be seen that no obvious poisoning manifestations occurred in the rats during the test, and no animals died, indicating that the composition prepared by the present invention is non-toxic.

[0030] Experiment 3: Stability and sensory evaluation test of calcium tablets with the effects of preventing calcium loss, promoting calcium absorption, and protecting joints Accelerated shelf-life tests were carried out on Application Examples 1-3. The calcium tablets were packaged in polyethylene-sealed glass bottles. The acceleration conditions were temperature: 40°C, relative humidity: 75%, and acceleration time: 8 weeks. Samples were taken for testing at 0, 2, 4, 6, and 8 weeks. The detection indexes included the color, taste, and texture state of the calcium tablets during the acceleration period. The evaluation methods for the above indexes are as follows: At different acceleration time points, 20 sensory evaluation personnel were respectively invited to evaluate the above samples. The evaluation method was blind sample (the 3 groups of samples were randomly marked as A, B, and C). The evaluation method: Take the same number of samples as the sensory evaluation personnel and place them on a porcelain plate. Observe the color and texture state under natural light, smell the odor, rinse the mouth with warm boiled water, and taste the taste.

[0031] Experimental results: For the calcium tablets in Application Examples 1 - 3 at week 0, their color and luster were uniform; taste and smell: had the unique taste and smell of the product, without abnormal smell; tissue state: dry and uniform flaky products, without impurities visible to normal vision. After eight - week accelerated test, compared with week 0, there were no differences visible to normal vision for the calcium tablets in Application Examples 1 - 3 at week 8, and their properties were stable.

[0032] Application Example 1: A calcium tablet with the effects of preventing calcium loss, promoting calcium absorption, and protecting joints, the calcium tablet comprising the following components in parts by mass: Glucosamine chondroitin composition (Composition 1): 55 parts; Magnesium oxide: 7 parts; Magnesium stearate: 1.3 parts; Xylitol: 10 parts; Sorbitol: 4 parts; Vitamin D3: 0.2 parts; 3wt% Povidone K30 solution: 5.5 parts; The 3wt% Povidone K30 solution is made by dissolving Povidone K30 in absolute ethanol; The preparation method of the calcium tablet comprises the following steps: S1. Pass magnesium oxide, xylitol, sorbitol, and vitamin D3 through an 80 - mesh sieve respectively and then mix them to obtain a mixture. Add the Povidone K30 solution to the mixture to make wet granules, and granulate with a 16 - mesh sieve shaker; S2. Dry the granules obtained in S1 at 38°C for 0.75 h, and then screen them with a 20 - mesh sieve; S3. Mix the granules obtained in S2 and magnesium stearate evenly by the equal - increment method, press them into tablets with a tablet press to obtain the finished calcium tablets, and bottle them.

[0033] Application Example 2: A calcium tablet with the effects of preventing calcium loss, promoting calcium absorption, and protecting joints, the calcium tablet comprising the following components in parts by mass: Glucosamine chondroitin composition (Composition 1): 50 parts; Magnesium oxide: 10 parts; Magnesium stearate: 0.5 parts; Xylitol: 15 parts; Sorbitol: 2 parts; Vitamin D3: 0.3 parts; 3wt% Povidone K30 solution: 5 parts; The 3wt% Povidone K30 solution is made by dissolving Povidone K30 in absolute ethanol; The preparation method of the calcium tablet comprises the following steps: S1. After passing magnesium oxide, xylitol, sorbitol, and vitamin D3 through an 80-mesh sieve respectively, mix them to obtain a mixture. Add a polyvinylpyrrolidone K30 solution to the mixture to make wet granules, and granulate by shaking through a 16-mesh sieve; S2. After drying the granules obtained in S1 at 38 °C for 0.5 h, size them through a 20-mesh sieve; S3. Mix the granules obtained in S2 and magnesium stearate evenly by the equal increment method, and press tablets with a tablet press to obtain the finished calcium tablets, then bottle them.

[0034] Application Example 3: A calcium tablet with the effects of preventing calcium loss, promoting calcium absorption, and protecting joints. The calcium tablet comprises the following components in parts by mass: Glucosamine chondroitin composition (Composition 1): 60 parts; Magnesium oxide: 5 parts; Magnesium stearate: 2 parts; Xylitol: 5 parts; Sorbitol: 5 parts; Vitamin D3: 0.1 part; 3wt% polyvinylpyrrolidone K30 solution: 6 parts; The 3wt% polyvinylpyrrolidone K30 solution is made by dissolving polyvinylpyrrolidone K30 in absolute ethanol; The preparation method of the calcium tablet comprises the following steps: S1. After passing magnesium oxide, xylitol, sorbitol, and vitamin D3 through an 80-mesh sieve respectively, mix them to obtain a mixture. Add a polyvinylpyrrolidone K30 solution to the mixture to make wet granules, and granulate by shaking through a 16-mesh sieve; S2. After drying the granules obtained in S1 at 38 °C for 1 h, size them through a 20-mesh sieve; S3. Mix the granules obtained in S2 and magnesium stearate evenly by the equal increment method, and press tablets with a tablet press to obtain the finished calcium tablets, then bottle them.

[0035] The embodiments described above are some embodiments of the present invention, not all of them. The detailed description of the embodiments of the present invention is not intended to limit the scope of the present invention claimed, but merely represents selected embodiments of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without creative efforts fall within the scope of protection of the present invention.

Claims

1. A glucosamine chondroitin composition, characterized in that Contains the following raw materials by weight: Turmeric extract: 2-4 parts; Drynaria fortunei extract: 5-8 parts; Eucommia ulmoides extract: 4-7 parts; Rehmannia root extract: 3-5 parts; Vitamin K: 2-6 servings; Bovine collagen peptide: 5-10 parts; Chondroitin sulfate: 2-4 parts; Glucosamine hydrochloride: 3-6 parts; Milk calcium: 20-30 portions; The vitamin K consists of vitamin K1 and vitamin K2, wherein the mass ratio of vitamin K1 to vitamin K2 is 1:0.5-1.

5.

2. The glucosamine chondroitin composition according to claim 1, characterized in that: Contains the following raw materials by weight: Turmeric extract: 3 parts; Drynaria extract: 6 parts; Eucommia ulmoides extract: 6 parts; Rehmannia glutinosa extract: 4 parts; Vitamin K: 4 parts; Bovine collagen peptide: 7 parts; Chondroitin sulfate: 3 parts; Glucosamine hydrochloride: 5 parts; Milk calcium: 25 parts; The vitamin K consists of vitamin K1 and vitamin K2, wherein the mass ratio of vitamin K1 to vitamin K2 is 1:

1.

3. Use of the glucosamine chondroitin composition as claimed in claim 1 or 2 in the preparation of health products.

4. The use according to claim 3, characterized in that: The health product is a nutritional supplement that prevents calcium loss, promotes calcium absorption, and protects joints.

5. The application according to claim 4, characterized in that: The nutritional supplement is in the form of oral liquid, drops, tablets, capsules, and powders.

6. A calcium tablet having the functions of preventing calcium loss, promoting calcium absorption and protecting joints, characterized in that: A glucosamine chondroitin composition comprising the glucosamine chondroitin composition according to claim 1 or 2.

7. The calcium tablet according to claim 6, characterized in that: Contains the following components by mass: The glucosamine chondroitin composition of claim 1 or 2: 50-60 parts; Magnesium oxide: 5-10 parts; Magnesium stearate: 0.5-2 parts; Xylitol: 5-15 parts; Sorbitol: 2-5 parts; Vitamin D3: 0.1-0.3 parts; 3wt% povidone K30 solution: 5-6 parts; The 3 wt % povidone K30 solution is prepared by dissolving povidone K30 in anhydrous ethanol.

Images